Lantern Pharma Inc., a leading artificial intelligence (AI) oncology drug discovery and development company, announced a strategic AI-driven collaboration with French biotechnology company, Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase (PDI) inhibitor drug candidate XCE853 in novel and targeted cancer indications. Lantern will be leveraging its proprietary RADR® AI platform to uncover biomarkers and efficacy-associated signatures of XCE853 across solid tumors that can aid in precision development. Collaborative efforts are expected to identify biomarker signatures that can be used to stratify tumors most responsive to XCE853 and guide potential future clinical development and patient selection. Oregon Therapeutics is developing XCE853 in various cancer indications, including drug-resistant ovarian and pancreatic cancer, certain hematological cancers and several pediatric cancers including CNS cancers.
PDIs are promising targets for cancer therapy raising clinical interest recently2 notably for their potential in cancers of poor prognosis like breast cancer3 or ovarian cancer. Up-regulated expression of PDIs was found to be associated with worse clinical outcome in numerous cancers such as hepatocellular carcinoma(4), as well as breast and ovarian cancers(5). PDIs are protein chaperones and are central to maintaining cancer cell metabolism, additionally PDI inhibitors can cause cancer cell death through the accumulation of impaired proteins and dysregulated cellular stress responses. A combination of these effects is known as proteotoxicity, a unique and promising therapeutic strategy that may be especially effective in targeting cancers that are resistant to therapy.
“To date, our first-in-class metabolic inhibitor, XCE853, has exhibited robust preclinical efficacy in both in vitro and in vivo models across multiple cancer types,” said Marc-Henry PITTY, MD, CEO of Oregon Therapeutics. “Lantern’s RADR® AI platform will leverage the in vitro and in vivo data to potentially advance XCE853 development in a highly targeted manner and will help inform disease indications and biomarker signatures that can aid in the design of future clinical trials and in the pursuit of combination therapies with other approved cancer drugs. Our team is looking forward to efficiently selecting among the landscape of ideal development options and efficiently de-risking future clinical development decisions.” Oregon Therapeutics has previously performed preclinical studies indicating that in addition to ovarian and pancreatic cancer, XCE853 may also be particularly active in renal, prostate, lung, breast, and head and neck cancers, and leukemia based on preclinical cell-line studies. Oregon project leader, Sandrine Courtès PhD, who has been developing the collaboration with Lantern Pharma, stated: “PDIs Inhibitors have a great potential, since this molecular target is highly expressed in several cancer types, supports tumor growth and is associated with clinical outcomes.”
Also Read: Araceli Biosciences Introduces Matt Beaudet as New President and Chief Executive Officer
The collaboration focuses on the integration and interrogation of molecular, genetic and transcriptomic data pertaining to XCE853. This analysis will be powered by RADR® and its growing library of over 60 billion data points from many diverse types of biological measurements and oncology experiments, as well as more than 200 ML algorithms focused on problems that are central to real-world cancer drug development. The initial objectives of the collaboration are to:
1) uncover biomarkers and efficacy-associated gene signatures to guide in the eventual stratification and selection of patients for future clinical trials,
2) identify tumor-based response and resistance mechanisms to XCE853 and strategies to overcome treatment resistance, and
3) expand the use of XCE853 in additional therapeutic cancer indications for XCE853.
“Drug development teams have found significant data and modeling challenges in regard to tackling the complexities associated with PDI inhibitors given the challenges with creating meaningful models, and accumulating and deciphering the data,” said Panna Sharma, CEO and President of Lantern Pharma. “Our AI platform, RADR®, can increase the confidence, insights, and comfort levels in developing data-driven development paths by modeling highly complex scenarios at a scale that only has become possible recently. It’s an ideal approach for Oregon Therapeutics, which has executed a series of highly targeted in vivo and in vitro experiments and is poised to make incredibly important and patient-centric decisions about the clinical future of the molecule. That’s where RADR® can play a highly essential and market defining role.”
SOURCE: Businesswire